-
Introducing the Stem Cell and Organoid Core
The Stem Cell and Organoid Core provides full-service support to produce human-induced pluripotent stem cells and isolate and expand human tissue-derived adult stem cells.
-
Induced pluripotent stem cell services
The Stem Cell and Organoid Core supports and accelerates research across Mayo Clinic by providing routine access to human stem cells and microphysiological systems and delivering state-of-the-art stem cell and organoid development services.
-
Future induced pluripotent stem cell services
By the second quarter of 2025, the Stem Cell and Organoid Core also will offer more induced pluripotent stem cell services. Additional service lines by the end of 2025 will greatly expand support for organoid and microphysiological systems development.
-
Tissue-derived stem cell services
By the second quarter of 2025, the Stem Cell and Organoid Core also will offer tissue-derived stem cell services.
Overview
The Stem Cell and Organoid Core provides researchers with access to high-quality, human-induced pluripotent stem cells (iPSCs), adult tissue-derived stem cells, and stem cell and tissue-derived organoids. The core supports and accelerates research across Mayo Clinic by providing routine access to human stem cells and microphysiological systems and delivering state-of-the-art stem cell and organoid development services.
The Stem Cell and Organoid Core is a direct outgrowth of the Cells2Cures Initiative led by Y.S. Prakash, M.D., Ph.D., associate dean of Research, Midwest. The core takes over the iPSC services previously provided by the Biotrust within the Center for Regenerative Biotherapeutics.